Clicky

uniQure N.V.(QURE)

Description: uniQure BV, a biopharmaceutical company, develops gene therapies through its modular technology platform for the treatment of genetic or acquired diseases. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency, an orphan metabolic disease. It also develops a pipeline of additional adeno-associated virus (AAV) based gene therapies, including AMT-060, a gene therapy for the treatment of hemophilia B; AMT-021 for acute intermittent porphyria; AMT-110 for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease, as well as various programs that are in early preclinical development stage. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, and University of California San Francisco. uniQure BV was founded in 1998 and is headquartered in Amsterdam, the Netherlands.


Keywords: Biopharmaceutical Biology Disease Parkinson's Disease Clinical Development Gene Therapy Genetics Metabolic Disease Hemophilia Applied Genetics Gene Delivery Lipoprotein Treatment Of Hemophilia Adeno Associated Virus Hemophilia B Lipase Lipoprotein Lipase Deficiency Acute Intermittent Porphyria Alipogene Tiparvovec Glybera Institut Pasteur

Home Page: www.uniqure.com

QURE Technical Analysis

Paasheuvelweg 25a
Amsterdam, 1105 BP
Netherlands
Phone: 31 20 240 6000


Officers

Name Title
Mr. Matthew Craig Kapusta CEO & Exec. Director
Mr. Christian Klemt CFO, Principal Financial Officer & GM of Amsterdam Site
Mr. Pierre Caloz Chief Operating Officer
Dr. Alexander E. Kuta Ph.D. Exec. VP of Quality & Regulatory Affairs
Dr. Ricardo Dolmetsch Ph.D. Pres of R&D
Prof. Hugo Katus Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
Mr. David Cerveny Chief Legal Officer, Gen. Counsel & Sec.
Dr. Tamara Tugal Ph.D., MBA Bus. Devel. Director
Ms. Erin Boyer Chief People & Culture Office
Ms. Maria E. Cantor Chief Corp. Affairs Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 27.933
Trailing PE: 2.8276
Price-to-Book MRQ: 2.6144
Price-to-Sales TTM: 17.5893
IPO Date: 2007-06-20
Fiscal Year End: December
Full Time Employees: 463
Back to stocks